These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 33527058)
21. Romiplostim-related myelofibrosis in refractory primary immune thrombocytopenia: A Case report. Kim HY; Park SW; Kim JH; Kang JH; Lee WS; Song HN Medicine (Baltimore); 2019 Jun; 98(25):e15882. PubMed ID: 31232923 [TBL] [Abstract][Full Text] [Related]
22. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP). Bussel JB; Hsieh L; Buchanan GR; Stine K; Kalpatthi R; Gnarra DJ; Ho RH; Nie K; Eisen M Pediatr Blood Cancer; 2015 Feb; 62(2):208-213. PubMed ID: 25345874 [TBL] [Abstract][Full Text] [Related]
23. Romiplostim: a review of its use in immune thrombocytopenia. Keating GM Drugs; 2012 Feb; 72(3):415-35. PubMed ID: 22316355 [TBL] [Abstract][Full Text] [Related]
24. Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP). McMillan R; Wang L; Tani P J Thromb Haemost; 2003 Mar; 1(3):485-91. PubMed ID: 12871454 [TBL] [Abstract][Full Text] [Related]
25. The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim. Deuson R; Danese M; Mathias SD; Schoonen M; Fryzek J J Med Econ; 2012; 15(5):956-76. PubMed ID: 22533524 [TBL] [Abstract][Full Text] [Related]
26. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Kuter DJ; Bussel JB; Lyons RM; Pullarkat V; Gernsheimer TB; Senecal FM; Aledort LM; George JN; Kessler CM; Sanz MA; Liebman HA; Slovick FT; de Wolf JT; Bourgeois E; Guthrie TH; Newland A; Wasser JS; Hamburg SI; Grande C; Lefrère F; Lichtin AE; Tarantino MD; Terebelo HR; Viallard JF; Cuevas FJ; Go RS; Henry DH; Redner RL; Rice L; Schipperus MR; Guo DM; Nichol JL Lancet; 2008 Feb; 371(9610):395-403. PubMed ID: 18242413 [TBL] [Abstract][Full Text] [Related]
27. Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry. Doobaree IU; Newland A; McDonald V; Nandigam R; Mensah L; Leroy S; Seesaghur A; Patel H; Wetten S; Provan D Eur J Haematol; 2019 May; 102(5):416-423. PubMed ID: 30758874 [TBL] [Abstract][Full Text] [Related]
28. Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia. Lozano ML; Godeau B; Grainger J; Matzdorff A; Rodeghiero F; Hippenmeyer J; Kuter DJ Expert Rev Hematol; 2020 Dec; 13(12):1319-1332. PubMed ID: 33249935 [No Abstract] [Full Text] [Related]
29. Uncommon Presentation of Sarcoidosis with Severe Thrombocytopenia and Hemorrhagic Diathesis. Lame D; Pianelli M; Kordasti S; Morsia E; Olivieri A; Poloni A Hematol Rep; 2024 Mar; 16(1):125-131. PubMed ID: 38534883 [TBL] [Abstract][Full Text] [Related]
31. Chronic immune thrombocytopenia in a child responding only to thrombopoietin receptor agonist. Osman ME Sudan J Paediatr; 2012; 12(2):60-4. PubMed ID: 27493347 [TBL] [Abstract][Full Text] [Related]
32. Romiplostim as a treatment for immune thrombocytopenia: a review. Chalmers S; Tarantino MD J Blood Med; 2015; 6():37-44. PubMed ID: 25632241 [TBL] [Abstract][Full Text] [Related]
33. The pathogenesis of chronic immune thrombocytopenic purpura. McMillan R Semin Hematol; 2007 Oct; 44(4 Suppl 5):S3-S11. PubMed ID: 18096470 [TBL] [Abstract][Full Text] [Related]
34. Mouse Models for Immune-Mediated Platelet Destruction or Immune Thrombocytopenia (ITP). Neschadim A; Branch DR Curr Protoc Immunol; 2016 Apr; 113():15.30.1-15.30.13. PubMed ID: 27038460 [TBL] [Abstract][Full Text] [Related]
35. Autoimmune thrombocytopenia: flow cytometric determination of platelet-associated CD154/CD40L and CD40 on peripheral blood T and B lymphocytes. Meabed MH; Taha GM; Mohamed SO; El-Hadidy KS Hematology; 2007 Aug; 12(4):301-7. PubMed ID: 17654056 [TBL] [Abstract][Full Text] [Related]
36. Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies. Kuter DJ; Newland A; Chong BH; Rodeghiero F; Romero MT; Pabinger I; Chen Y; Wang K; Mehta B; Eisen M Br J Haematol; 2019 May; 185(3):503-513. PubMed ID: 30793285 [TBL] [Abstract][Full Text] [Related]
37. Response loss and development of neutralizing antibodies during long-term treatment with romiplostim in patients with immune thrombocytopenia: a case series. Carpenedo M; Cantoni S; Coccini V; Pogliani EM; Cairoli R Eur J Haematol; 2016 Jul; 97(1):101-103. PubMed ID: 26718013 [TBL] [Abstract][Full Text] [Related]
38. Total remission of severe immune thrombocytopenia after short term treatment with romiplostim. Vlachaki E; Papageorgiou V; Klonizakis F; Spandonidou M; Chisan S; Vetsiou E; Ioannidou E Hematol Rep; 2011 Oct; 3(3):e20. PubMed ID: 22593812 [TBL] [Abstract][Full Text] [Related]
39. Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials. Tarantino MD; Despotovic J; Roy J; Grainger J; Cooper N; Beam D; Raj A; Maschan A; Kim J; Eisen M Pediatr Blood Cancer; 2020 Nov; 67(11):e28630. PubMed ID: 32902132 [TBL] [Abstract][Full Text] [Related]
40. Pathophysiology of Autoimmune Thrombocytopenia: Current Insight with a Focus on Thrombopoiesis. Marini I; Bakchoul T Hamostaseologie; 2019 Aug; 39(3):227-237. PubMed ID: 30802916 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]